Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

519 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.
Takahashi S, Oridate N, Tanaka K, Shimizu Y, Fujimoto Y, Matsumoto K, Yokota T, Yamazaki T, Takahashi M, Ueda T, Hanai N, Yamaguchi H, Hara H, Yoshizaki T, Yasumatsu R, Nakayama M, Shiga K, Fujii T, Mitsugi K, Takahashi K, Nohata N, Gumuscu B, Swaby RF, Tahara M. Takahashi S, et al. Among authors: yoshizaki t. Int J Clin Oncol. 2022 Dec;27(12):1805-1817. doi: 10.1007/s10147-022-02233-6. Epub 2022 Oct 20. Int J Clin Oncol. 2022. PMID: 36264378 Free PMC article. Clinical Trial.
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators. Burtness B, et al. Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1. Lancet. 2019. PMID: 31679945 Clinical Trial.
An autopsy case of type A FTLD-TDP with a GRN mutation presenting with the logopenic variant of primary progressive aphasia at onset and with corticobasal syndrome subsequently.
Tomenaga T, Minatani S, Namba H, Takeda A, Yoshizaki T, Kawabe J, Keyoumu N, Morino H, Higuchi M, Matsubara T, Hatsuta H, Hasegawa M, Murayama S, Itoh Y. Tomenaga T, et al. Among authors: yoshizaki t. Neuropathology. 2024 May 7. doi: 10.1111/neup.12980. Online ahead of print. Neuropathology. 2024. PMID: 38715398
Lipoma Arising in the Eustachian Tube.
Inoue T, Kumai T, Yoshizaki T, Takahara M. Inoue T, et al. Among authors: yoshizaki t. Cureus. 2024 Mar 20;16(3):e56597. doi: 10.7759/cureus.56597. eCollection 2024 Mar. Cureus. 2024. PMID: 38646351 Free PMC article.
Randomised controlled, patient-blinded, multicentre, superiority trial to evaluate the efficacy of the line-attached sheath-type traction device for endoscopic submucosal dissection in patients with superficial gastric neoplasms.
Abe H, Sako T, Yamamoto Y, Ikeda A, Kawara F, Ose T, Takao T, Kitamura Y, Ariyoshi R, Morita Y, Ishida T, Ikegawa T, Ishida R, Yoshizaki T, Sakaguchi H, Toyonaga T, Kodama Y. Abe H, et al. Among authors: yoshizaki t. BMJ Open. 2024 Apr 17;14(4):e078974. doi: 10.1136/bmjopen-2023-078974. BMJ Open. 2024. PMID: 38631838 Free PMC article. Clinical Trial.
Enhancer infestation drives tumorigenic activation of inactive B compartment in Epstein-Barr virus-positive nasopharyngeal carcinoma.
Mizokami H, Okabe A, Choudhary R, Mima M, Saeda K, Fukuyo M, Rahmutulla B, Seki M, Goh BC, Kondo S, Dochi H, Moriyama-Kita M, Misawa K, Hanazawa T, Tan P, Yoshizaki T, Fullwood MJ, Kaneda A. Mizokami H, et al. Among authors: yoshizaki t. EBioMedicine. 2024 Apr;102:105057. doi: 10.1016/j.ebiom.2024.105057. Epub 2024 Mar 14. EBioMedicine. 2024. PMID: 38490101 Free PMC article.
519 results